---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pathophysiology"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pathophysiology. Topics: Urothelial carcinogen exposure and detoxification, Field defect and multifocal disease, Molecular drivers and transcriptomic classes of NMIBC, Molecular subtypes associated with response and failure after BCG, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Urothelial carcinogen exposure and detoxification

> “The aromatic amines and polycyclic aromatic hydrocarbons within the tobacco smoke, which undergo renal excretion, are linked to the development of BC.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “Smokers with less functional polymorphisms of N-acetyltransferase-2 (known as slow acetylators) have a higher risk of bladder cancer than other smokers, presumably because of their reduced ability to detoxify carcinogens.”
> “Chronic inflammation is thought to play a key role in carcinogenesis in these settings.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

<a id="topic-2.2.1.4-2"></a>

### Field defect and multifocal disease

> “Urothelial carcinomas are thought to reflect a so-called field defect, whereby the cancer emerges because of genetic variants that are widely present in the patient's bladder or entire urothelium.”
> “Thus, people who have had a bladder tumor resected often subsequently have recurrent tumors in the bladder, often in different locations from the site of the initial tumor.”
> “An alternative explanation for these patterns of recurrence is that cancer cells that are disrupted when a tumor is resected may reimplant elsewhere in the urothelium.”

Source: [National Cancer Institute PDQ Bladder Cancer Treatment (2025)](https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq)

> “Carcinoma in situ is often multifocal and can occur in the bladder, but also in the upper urinary tract, prostatic ducts and urethra”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.1.4-3"></a>

### Molecular drivers and transcriptomic classes of NMIBC

> “Activating mutations in FGFR3 and PIK3CA and chromosome 9 deletions have been identified as early disease drivers”
> “Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness.”
> “High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome.”
> “RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b.”

Source: [Lindskrog et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8052448/)

<a id="topic-2.2.1.4-4"></a>

### Molecular subtypes associated with response and failure after BCG

> “Here we conducted molecular profiling of 132 patients with BCG-naïve HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1–3).”
> “Patients with BRS3 tumors had reduced recurrence and progression-free survival compared to BRS1/2.”
> “BRS3 tumors expressed high EMT-basal markers and had an immunosuppresive profile, which was confirmed with spatial proteomics.”
> “BRS3-predicted tumors were enriched in post-BCG 28/44 (64%) recurrences vs pre-BCG tumors 82/283 (28%)”
> “From the 34 matched tumors, 26/34 patients had BRS1/ 2 tumors pre-BCG of which 14/26 tumors switched to BRS3 post-BCG.”

Source: [de Jong et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10572776/)

<a id="topic-2.2.1.4-5"></a>

### Adaptive immune resistance as a mechanism of BCG failure

> “The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders.”
> “Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01).”
> “PD-L1+ cells in BCG nonresponders colocalized with CD8+ T cells.”
> “One mechanism of BCG failure may be adaptive immune resistance.”

Source: [Kates et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712383/)

<a id="topic-2.2.1.4-6"></a>

### Biological differences between papillary-only and CIS-containing disease after BCG

> “A contemporary systematic review assessing 42 prospective trials on bladder-preserving treatments after BCG showed that patients with papillary-only recurrences appeared more effectively treated”
> “highlighting potential biological differences between these two tumour entities which should be analysed separately when reporting results of clinical trials”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

> “a prolonged versus a short disease-free interval may reflect different underlying biology.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
